Product :Nolvadex (Tamoxifen Citrate)
CAS No: 54965-24-1
MF: C26H29NO
MW: 371.51
Purity: 99%
Boiling point: 482.3°C at 760 mmHg
Storage: Sealed in the 2 ºC -8 ºC
Melting point:140-144 °C
flash point: 356.5ºC
Structure:
Einecs No: 234-118-0
Standard: Enterprise Standard
Usage:Tamoxifen is a female hormone which can blocks the actions of estrogen,it is usually used for treat some types of breast cancer in men and women. |
Breast Cancer
|
10 to 20 mg orally twice daily |
For metastatic breast cancer
|
20 to 40 mg given in divided |
Women with Ductal Carcinoma
|
20 mg daily for 5 years |
Reduce the incidence of breast cancer
|
20mg daily for 5 years |
Node-positive breast cancer,axillary dissection
|
10 mg orally 2 to 3 times daily for 5 years. |
Girls age 2 to 10 years with McCune-Albright Syndrome
|
20 mg daily for one year |
1:Tamoxifen Citrate Use in Cancer
Tamoxifen citrate |
Approved to prevent: Breast cancer in women who are at high risk for the disease. |
Breast cancer in women and men |
|
being studied in the treatment of other types of cancer. |
A. Tamoxifen slows or stops the growth of cancer cells that are already present in the body. It helps keep the original breast cancer from coming back and helps prevent new cancer in the opposite breast. It also reduces the risk of breast cancer in women who have a high risk for this disease.
B. Tamoxifen is used to prevent and treat breast cancers that test positive for estrogen receptors (ER+). It blocks the effects that the hormone estrogen has on cancer cells and lowers the chance that breast cancer will grow. It is often called an "anti-estrogen."
C. Tamoxifen is highly effective in lowering the risk of breast cancer recurrence. In women who have already had breast cancer, tamoxifen also lowers the risk of breast cancer in the opposite breast (contralateral)
D. For postmenopausal women, a two-stage treatment using tamoxifen and then an aromatase inhibitor, such as anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) may work better than only taking tamoxifen.
Product |
Tamoxifen Citrate / Nolvadex |
Test |
Analysis Standard |
Results |
Characteristics |
White crystalline powder |
conforms |
Assay |
99 ~ 101.0% |
99.51% |
Loss on drying |
≤0.5% |
0.24% |
Identification |
IR,UV conform |
conforms |
Residue on ignition |
≤0.2% |
0.06% |
Iron |
≤0.005% |
0.0016% |
Heavy metals |
≤0.001% |
0.0006% |
Related substances |
Total:≤1.0% |
0.37% |
Individual:≤0.5% |
0.17% |
|
E-isomer |
≤0.3% |
0.20% |
Organic volatile impurities |
conform |
conform |
Conclusion |
This batch is complies with USP 30. |